We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Santhera Pharmaceuticals Holding AG (SANN) CHF0.1

Sell:10.30 CHF Buy:10.50 CHF Change: 0.48 CHF (4.81%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:10.30 CHF
Buy:10.50 CHF
Change: 0.48 CHF (4.81%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:10.30 CHF
Buy:10.50 CHF
Change: 0.48 CHF (4.81%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.

Contact details

Address:
Hohenrainstrasse 24
PRATTELN
4133
Switzerland
Telephone:
+41 (61) 9068950
Website:
https://www.santhera.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SANN
ISIN:
CH1276028821
Market cap:
129.99 million CHF
Shares in issue:
11.72 million
Sector:
Biotechnology
Exchange:
SIX Swiss Exchange
Country:
Switzerland
Currency:
Swiss Franc
Indices:
Swiss All Share Index

Key personnel

  • Thomas Meier
    Chairman of the Board
  • Dario Eklund
    Chief Executive Officer, Member of the Executive Management Board
  • Andrew Smith
    Chief Financial Officer, Member of the Management Board
  • Guenther Metz
    Executive Vice President - Head Business Development, Member of the Executive Management Board
  • Oliver Strub
    Head of Compliance
  • Oliver Kronenberg
    Chief Legal Officer, Corporate Secretary, Member of the Executive Management Board
  • Shabir Hasham
    Chief Medical Officer and Member of the Executive Management Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.